Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

BACKGROUND: The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. METHODS: We present t...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Cortellini, Alessio, Ricciuti, Biagio, Tiseo, Marcello, Bria, Emilio, Banna, Giuseppe L, Aerts, Joachim GJV, Barbieri, Fausto, Giusti, Raffaele, Cortinovis, Diego L, Migliorino, Maria R, Catino, Annamaria, Passiglia, Francesco, Torniai, Mariangela, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Gelibter, Alain, Occhipinti, Mario Alberto, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Grossi, Francesco, Filetti, Marco, Pizzutilo, Pamela, Russano, Marco, Citarella, Fabrizio, Cantini, Luca, Targato, Giada, Nigro, Olga, Ferrara, Miriam G, Buti, Sebastiano, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Della Gravara, Luigi, Tabbò, Fabrizio, Ricciardi, Serena, De Toma, Alessandro, Friedlaender, Alex, Petrelli, Fausto, Addeo, Alfredo, Porzio, Giampiero, Ficorella, Corrado
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574933/
https://ncbi.nlm.nih.gov/pubmed/33077515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items